Kimberly J. Popovits - 30 Jul 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
30 Jul 2025
Net transactions value
-$1,164,623
Form type
4
Filing time
01 Aug 2025, 16:36:07 UTC
Previous filing
16 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Popovits Kimberly J Director 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Madelyn Zeylikman, Attorney-in-Fact 01 Aug 2025 0001333482

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise $473,949 +45,748 +365% $10.36 58,294 30 Jul 2025 Direct
transaction KNSA Class A Ordinary Share Options Exercise $290,217 +18,760 +32% $15.47 77,054 30 Jul 2025 Direct
transaction KNSA Class A Ordinary Share Options Exercise $1,928,789 -64,508 -84% $29.90 12,546 30 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -45,748 -100% $0.000000 0 30 Jul 2025 Class A Ordinary Shares 45,748 $10.36 Direct F2
transaction KNSA Share Option Options Exercise $0 -18,760 -100% $0.000000 0 30 Jul 2025 Class A Ordinary Shares 18,760 $15.47 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.66 and $30.07. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F2 The option is fully vested and exercisable.